MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (www.petvivo.com) (OTCMARKET:PETV), an emerging biomedical device company, is pleased to announce the addition of Dr. Tracy Turner of The Turner Equine Sports Medicine and Surgery clinic to their Advisory Board. Dr. Turner is renowned nationwide for his work over the years with horses. Dr. Turner consults for the USDA Horse Protection, Federation Equestrienne International (FEI) and United States Equestrian Federation. He has used the Kush™ System with various horses and is excited to join the team.
With Dr. Turner and Dr. Michael Sterns from San Francisco on board, PetVivo management has decided to form a Vet Advisory Board. The Board is an integral part of PetVivo’s overall Advisory Board.
The Vet Advisory Board is made up of four extremely prominent veterinarians from different areas of the USA. Dr. Tracy Turner from Minnesota and Dr. Brad Gordon from Iowa make up the equine group and Dr Brian Barnett founder of the Randolph Animal Hospital, North Carolina and Dr. Michael Sterns from San Francisco will make up the canine group. They will be available through PetVivo’s office to speak with vets that might have questions about the product and the treatment. PetVivo’s Vet Clinician, Cassandra Dwyer will be coordinating the calls and will be available in addition to help vets by calling our 1-800 help line. Additional information will be available on the PetVivo website.
“PetVivo Holdings, Inc. is privileged to have these four Doctors of Veterinary Medicine on our advisory board. Their advice and direction will provide assistance that few others can,” stated Wes Hayne, CEO of PetVivo.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 962-405-6216
Direct: (763) 443-7272